Skip to main content


for people ages 18 years and up (full criteria)
at San Francisco, California
study started



The primary objective of this study is to determine if Gallium-68 labeled DOTA-TOC will result in the delineation of more lesions in patients with somatostatin receptor positive malignancies than with conventional imaging.


Neuroendocrine Tumor Paraganglioma Carcinoid Tumors Neuroblastoma Neuroendocrine Tumors Carcinoid Tumor Carotid Body Tumor Somatostatin Edotreotide Octreotide


You can join if…

Open to people ages 18 years and up

  • Known or suspected somatostatin receptor positive tumor such as carcinoid;neuroendocrine tumor; neuroblastoma; pheochromocytoma. Supporting evidence may include MRI, CT, biochemical markers, and or pathology report.
  • Age > 18.
  • Karnofsky performance status of > 50 (or ECOG/WHO equivalent).
  • Not pregnant. A negative serum pregnancy test is required for all female subjects with child-bearing potential.
  • Ability to understand a written informed consent document, and the willingness to sign it

You CAN'T join if...

  • Hepatic enzymes 5 times greater than the upper limits of normal, serum creatinine >3.0 mg/dL (270 uM/L)
  • Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET/CT scanner due to BMI
  • Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,etc.)
  • Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
  • Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
  • Recognized concurrent active infection
  • Previous systemic or radiation treatment for another cancer of any type within the last 2 months
  • Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments.


  • UCSF Imaging Center at China Basin accepting new patients
    San Francisco, California, 94107, United States


in progress, not accepting new patients
Start Date
University of California, San Francisco
North American NeuroEndocrine Tumor Society
Phase 2
Lead Scientist
Thomas Hope
Study Type
Last Updated
September 2016